TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* present with type 2 diabetes mellitus~* HbA1c between 7.1% and 11.0% inclusive~* body mass index (BMI) of \>18kg/m2 and \<35kg/m2, inclusive~* treated with a stable dose regimen of either of biguanide (BG) alone, BG + thiazolidinedione (TZD), BG + sulfonylurea (SU), or BG + TZD + SU for 90 days prior to study start~Exclusion Criteria:~* Have received chronic (\>14 consecutive days) systemic adrenocorticosteroid therapy by oral, intravenous, or intramuscular route or intraarticular steroid injection within 4 weeks prior to study start.~* Have been treated with drugs that promote weight loss within 90 days prior to study start.~* Have been treated with drugs that directly affect gastrointestinal motility for \> 21 consecutive days within 90 days prior to study start.~* Have had prior exposure to exenatide BID or QW or participated in the clinical trial of exenatide BID or QW (including the case that the study drug was not administered).~* Have been treated for \>2 consecutive weeks with any of the following excluded medications within 90 days prior to study start: Insulin, Dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 analogs~* Have received treatment within 30 days prior to study start drug that has not received regulatory approval for any indication.~* Are currently enrolled in any other clinical study or participated in and completed the clinical study within 30 days prior to study start.~* Have donated blood within 30 days prior to study start.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- exenatide once weekly (Type: EXPERIMENTAL): None
- insulin glargine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients older than 18 years undergoing a PCI procedure~2. Pretreatment with 600mg clopidogrel at least 2 hours before the intervention~3. Informed, written consent by the patient or her/his legally-authorized representative for participation in the study.~Exclusion Criteria:~1. Recent ST-elevation myocardial infarction within the last 48 hours~2. Acute coronary syndromes with positive biomarkers (Troponin T \> 0.03 μg/L or CK-MB \> ULN)~3. Cardiogenic shock~4. Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than one year or that may result in protocol non-compliance~5. Active bleeding; bleeding diathesis~6. History of gastrointestinal or genitourinary bleeding within the last 6 weeks~7. Presence of diseases which have a high probability of vascular lesions and subsequent bleeding such as active gastric ulcer or active ulcerous colitis~8. Recent trauma or major surgery in the last month~9. Ophthalmic surgery or brain surgery in the last month~10. Retinopathies or vitreous body bleeding in the last month~11. History of intracranial bleeding or structural abnormalities (for example aneurysm of cerebral arteries)~12. Suspected aortic dissection; pericarditis and subacute bacterial endocarditis~13. Patient's refusal to blood transfusion.~14. Oral anticoagulation therapy with coumarin derivative within the last 7 days~15. Treatment with UFH within 6 hours unless an ACT is less than 150 sec or low-molecular weight heparin within 8 hours before enrollment~16. Treatment with bivalirudin within 24 hours before enrollment~17. Severe uncontrolled hypertension \>180/110 mmHg unresponsive to therapy~18. Planned staged PCI procedure within 30 days from index procedure or prior PCI within the last 30 days.~19. Relevant hematologic deviations: hemoglobin \< 100 g/L, platelet count \< 100 x 109 /L.~20. Glomerular filtration rate (GFR) \< 30 ml/min or serum creatinine \> 30 mg/L or dependence on renal dialysis.~21. Known allergy to the study medications: aspirin, clopidogrel, UFH, true anaphylaxis after prior exposure to contrast media.~22. Known heparin-induced thrombocytopenia (Typ II)~23. Previous enrollment in this trial.~24. Pregnancy (present, suspected or planned) or positive pregnancy test.~25. Spinal, peridural and epidural anesthesia~26. Patient's inability to fully cooperate with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reduced dose of unfractionated heparin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Successful completion of Core Study~* At least 6 years of age~* Males and females

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically and/or histologically confirmed NSCLC Stage IIIb or IV~* No previous systemic chemotherapy for this cancer~* At least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria In Solid Tumors (RECIST) criteria~* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 and adequate organ function~* Prior radiation therapy allowed but limited to \<25% of the patient's bone marrow~Exclusion Criteria:~* Serious concomitant systemic disorder or active infection~* Mild to moderate renal insufficiency, but unable to interrupt salicylates or other nonsteroidal anti-inflammatory drugs~* Symptomatic central nervous system (CNS) metastases requiring concurrent corticosteroid therapy~* Presence of clinically significant third-space fluid collections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Cisplatin (Type: EXPERIMENTAL): None
- Pemetrexed + Carboplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria:~* 18 years of age or older at time of consent~* Active Psoriatic Arthritis~* Clinically stable, plaque psoriasis involving more than 10% of the body surface area~Exclusion Criteria:~Exclusion Criteria:~* Evidence of skin conditions other than psoriasis that would interfere with skin examinations.~* Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation~* Prior exposure to any TNF-inhibitor, including etanercept

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Period 1 (Double Blind): 50mg bi-weekly (BIW) for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW).
- B (Type: ACTIVE_COMPARATOR): Period 1 (Double Blind): 50mg weekly (QW) with matching placebo for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW) for weeks 13-24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Injection Lypolysis (Lipodissolve) Treatments to Reduce Body Fat

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer~* Body Mass Index (BMI) no greater than 30~* Excess fat in the lower abdomen area~Exclusion Criteria:~* Cigarette smoker~* Diabetes~* Pregnant or breast feeding~* Use anticoagulants (blood thinner), aspirin or other non-steroidal anti-inflammatory drugs that cannot be discontinued

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with an dual chamber ICD or CRTD (with an existing functional atrial lead) with remote monitoring capabilities and EF \<= 40% within the last 3 months by echocardiogram, nuclear imaging, MRI or cardiac catheterization,~2. Persistent or chronic symptomatic AF resistant to anti-arrhythmic medication other than Amiodarone. Resistant defined as recurrent AF of greater than 5 minutes duration at least once per month.~3. Therapeutic anticoagulation for at least three weeks prior to initiation of therapy~4. Ability to complete 6 minute walk test.~5. Age \>= 18 years old. (Females must be either post-menopausal \>12 months, practicing a protocol-acceptable method of birth control \[defined as injectable or implantable hormonal contraceptives, oral contraceptives, intrauterine device, diaphragm plus spermicide\], or have had a hysterectomy, bilateral oophorectomy, or tubal ligation performed at least 6 months prior to enrollment).~6. All patients optimized on CHF medications including beta-blocker and ace-inhibitor or angiotensin-receptor blocker.~7. patients receiving low dose amiodarone- \<200 mg for 2 or less months~Exclusion Criteria:~The exclusion criteria are:~1. Reversible causes of AF such as pericarditis, hyperthyroidism,~2. Presently with Valvular Heart disease requiring surgical intervention~3. Presently with coronary artery disease requiring surgical intervention~4. Early Post-operative AF (within three months of surgery)~5. Previous MAZE or left atrial instrumentation~6. Prolonged QT interval~7. Hypothyroidism~8. Liver Failure~9. Life expectancy \<= 2 years~10. Social factors that would preclude follow up or make compliance difficult.~11. Contraindication to the use of anti-arrhythmic medications and/or coumadin and heparin~12. Enrollment in another investigational drug or device study.~13. Patients with severe pulmonary disease i.e. COPD or asthma~14. Documented intra-atrial thrombus, tumor, or another abnormality which precludes catheter introduction~15. Any ophthalmologic disorders (other than requiring glasses for vision correction)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AF ablation (Type: ACTIVE_COMPARATOR): Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting.
- Amiodarone (Type: ACTIVE_COMPARATOR): Amiodarone is taken orally on a daily basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent/assent: For patients 18 to 50 years of age, inclusive, written informed consent signed and dated by the patient before conducting any study related procedures and review of Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization; for patients 12 to 17 years of age, inclusive, written informed consent signed and dated by the parent/legal guardian and written assent signed and dated by the patient before conducting any study related procedure and review of HIPAA authorization.~* Male or female patients 12 to 50 years of age, inclusive, as of SV1.~* If female, is currently not pregnant, breastfeeding, or attempting to become pregnant, has a negative serum pregnancy test, and is of non-childbearing potential.~* Documented history of EIB, with or without underlying asthma. The underlying asthma must be well-controlled (in the investigator's judgment) as per the National Asthma Education and Prevention Program, Expert Panel Report (NAEPP, EPR-3).~* Other criteria apply.~Exclusion Criteria:~* Requires a rescue bronchodilator following the exercise challenge at SV1 for a decrease in FEV1 that does not return to within 20% of their pre-exercise challenge FEV1 within 30 minutes after administration of the rescue medication.~* Pregnant, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days after the patient's last study related visit (for eligible patients only-if applicable).~* Participation in any investigational drug trial within the 30 days preceding SV1 or planned participation in another investigational drug trial at any time during this trial.~* A known hypersensitivity to albuterol or any of the excipients in the formulation.~* History of severe milk protein allergy.~* History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, otitis media, acute or chronic sinusitis, influenza, etc) that has not resolved within the 2 weeks preceding SV1.~* Other criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Albuterol Spiromax / Placebo Spiromax (Type: EXPERIMENTAL): Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
- Placebo Spiromax / Albuterol Spiromax (Type: EXPERIMENTAL): Placebo Spiromax, (2 inhalations), single dose on Day 1. Albuterol Spiromax 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on approximately Day 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly subjects with psychosis~Exclusion Criteria:~* Have an uncontrolled, unstable clinically significant~medical condition.~* Have an established diagnosis of dementia

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine 2-10 mg BID (Type: EXPERIMENTAL): Dose titration from 2 mg to 5 mg to 10 mg twice daily (BID)
- Asenapine 5-10mg BID (Type: EXPERIMENTAL): Dose titration from 5 mg to 10 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA class I or II~* Elective transurethral prostatectomy~* aged \> 20~Exclusion Criteria:~* Coagulation deficiency~* infection on the back~* Congestive heart failure or arrythmia~* Chronic alcoholic disease~* Antidepressants therapy

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bupivacaine (Type: ACTIVE_COMPARATOR): 0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
- saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Combination Therapy With SYR-322

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject is an outpatient.~2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.~Exclusion Criteria:~1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.~2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYR-322 (Alogliptin) QD (Type: EXPERIMENTAL): SYR-322 25 mg, orally.
- Insulin (Type: PLACEBO_COMPARATOR): injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Male and female patients with a diagnosis of CAP and all criteria listed below:~1. Age 18 or above, no upper age limit will be employed.~2. Patients must require hospitalisation.~3. Clinical presentation of an acute illness with one or more of the following symptoms:~   1. Temperature ≥ 38.0 ⁰C (100.4°F)~  2. Dyspnoea~  3. Cough (with or without expectoration of sputum)~  4. Chest pain~  5. Malaise or fatigue~  6. Myalgia~  7. Gastro-intestinal symptoms~  8. Rales, rhonchi or wheezing~  9. Egophony or bronchial breath sounds~4. New consolidation(s) on the chest radiograph.~5. Written informed consent obtained.~6. (Pre-event) Life expectancy \> 30 days~Exclusion Criteria:~Subjects presenting with any of the following will not be included in the study:~1. (Severe) immunosuppression (e.g. HIV infection, chemotherapy, use of immunosuppressants).~2. Active neoplastic disease.~3. Obstruction pneumonia (e.g. from lung cancer).~4. Aspiration pneumonia.~5. Pneumonia that developed within 8 days after hospital discharge.~6. Unable and/or unlikely to comprehend and/or follow the protocol.~7. Pregnant and/or lactating women.~8. Other infection that requires treatment with antibiotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Common clinical practice (Type: ACTIVE_COMPARATOR): Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
- CRP-guided treatment (Type: EXPERIMENTAL): Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
- PCT guided treatment (Type: EXPERIMENTAL): Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of of Olodaterol and Ketoconazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria Healthy male and female volunteers~Exclusion criteria

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- BI 1744 10 mcg (Type: EXPERIMENTAL): solution for oral inhalation
- Ketoconazole 400 mg (Type: EXPERIMENTAL): tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete